OncUpdates· @OncUpdates · X·· 14 hours agoScore70
Body · original
🚨 #ESMO26 | INTerpath-001: Personalized mRNA neoantigen vaccine (intismeran) + pembrolizumab vs placebo + pembrolizumab in resected stage IIB–IV melanoma 💉
✅ 2-yr RFS: 82.2% vs 70.0%
✅ 2-yr DMFS: 88.5% vs 80.2%
⚠️OS immature
#Melanoma #OncTwitter #medX #MedTwitter
27 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: OncUpdates · x.com